Clinical Trials Logo
  1. Home
  2. Recurrent Glioma
  3. NCT01580969

Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma — RAMBO  

Recurrent Glioma Clinical Trial

Official title:
A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab in Patients With Recurrent gliOma (RAMBO)

Clinical Trial Summary

The primary objective of step 1 is the rate of adverse events of minocycline and bevacizumab during reirradiation and of step 2 is the response rate to bevacizumab, reirradiation, and minocycline. The secondary objectives are the response rate, Progression Free Survival (PFS)-3, PFS-6, and effects on quality of life and cognition from repeat radiation and bevacizumab.

Clinical Trial Description

After providing informed consent, patients will undergo screening for eligibility to participate in the study. Screening will start within 21 days prior to dosing.

Subjects will have an MRI within 21 days of starting radiation. QOL and cognition measures will be performed within 21 days of starting radiation. Radiation will be given with parameters determined on an individual basis by the radiation oncologist. Bevacizumab will be continued at 10mg/kg IV every 2 weeks. Minocycline will be given twice a day starting at 100mg PO bid. MRI, QOL, and cognitive tests will be obtained 1, 3 and 6 months after the end of radiation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01580969
Study type Interventional
Source University of Utah
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 6, 2012
Completion date May 15, 2018
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT05045027 - Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma Early Phase 1
Not yet recruiting NCT04562077 - Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
Active, not recruiting NCT05611645 - Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence Phase 2
Completed NCT04089449 - A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas Phase 1
Active, not recruiting NCT03213678 - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03698994 - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Terminated NCT01324635 - Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors Phase 1
Recruiting NCT05406700 - Niraparib In Recurrent IDH 1/2 Gliomas Early Phase 1
Recruiting NCT05660369 - CARv3-TEAM-E T Cells in Glioblastoma Phase 1
Recruiting NCT03796273 - Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Early Phase 1
Terminated NCT05297864 - PARP Inhibition for Gliomas (PI-4G or π4g) Phase 2
Not yet recruiting NCT06397560 - PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial N/A
Recruiting NCT03155620 - Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Phase 2
Recruiting NCT04943718 - Personalized Vaccine for Patients With Recurrent Malignant Glioma Phase 1
Active, not recruiting NCT04164901 - Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) Phase 3
Active, not recruiting NCT03212274 - Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Phase 2
Recruiting NCT04740190 - Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd Phase 2
Recruiting NCT04216550 - Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas